metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
non squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) non squamous cell - mNSCLC - L2 non squamous - mNSCLC - L2 - all population
versus docetaxel
	nivolumab alone vs. docetaxel	1	suggested 68 % decrease in AE (any grade)	inconclusive results for: progression or deaths (PFS); DOR; Acute kidney injury TRAE (grade 3-4); Alopecia TRAE (grade 3-4); Anaemia TRAE (grade 3-4); Arthralgia TRAE (grade 3-4); Asthenia TRAE (grade 3-4); Blood creatinine increased TRAE (grade 3-4); Colitis TRAE (grade 3-4); Constipation TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diabetes TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Dysgeusia TRAE (grade 3-4); Eczema TRAE (grade 3-4); Erythema TRAE (grade 3-4); Hypersensitivity TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Increase AST TRAE (grade 3-4); Increased ALT TRAE (grade 3-4); Increased lacrimation (TRAE grade 3-4); Infusion-related reactions TRAE (grade 3-4); Maculopapular rash TRAE (grade 3-4); Mucosal inflammation TRAE (grade 3-4); Myalgia TRAE (grade 3-4); Nausea TRAE (grade 3-4); Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4); Paraesthesia TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4); Peripheral oedema TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Pruritic rash TRAE (grade 3-4); Pruritus generalised TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Pyrexia TRAE (grade 3-4); Rash TRAE (grade 3-4); Skin exfoliation TRAE (grade 3-4); Stomatitis TRAE (grade 3-4); Thyroiditis TRAE (grade 3-4); Urticaria TRAE (grade 3-4); Vomiting TRAE (grade 3-4); Abdominal pain AE (grade 3-4); Alopecia AE (grade 3-4); Anaemia AE (grade 3-4); Arthralgia AE (grade 3-4); Asthenia AE (grade 3-4); Back pain AE (grade 3-4); Constipation AE (grade 3-4); Cough AE (grade 3-4); Decreased appetite AE (grade 3-4); Diarrhoea AE (grade 3-4); Dizziness AE (grade 3-4); Dry skin AE (grade 3-4); Dysgeusia AE (grade 3-4); Dyspnoea AE (grade 3-4); Erythema AE (grade 3-4); Fatigue AE (grade 3-4); Headache AE (grade 3-4); Hypothyroidism AE (grade 3-4); Increased ALT AE (grade 3-4); Lacrimation increased AE (grade 3-4); Mucosal inflammation AE (grade 3-4); Myalgia AE (grade 3-4); Nausea AE (grade 3-4); Oropharyngeal pain AE (grade 3-4); Paraesthesia AE (grade 3-4); Peripheral neuropathy AE (grade 3-4); Peripheral oedema AE (grade 3-4); Pneumonia AE (grade 3-4); Pruritus AE (grade 3-4); Pyrexia AE (grade 3-4); Rash AE (grade 3-4); Stomatitis AE (grade 3-4); Vomiting AE (grade 3-4); Weight decreased AE (grade 3-4)	statistically conclusive 27 % decrease in deaths (OS) but the degree if certainty is unassessable statistically conclusive 70 % increase in objective responses (ORR) but the degree if certainty is unassessable suggested 58 % decrease in AE (grade 3-4) but the degree if certainty is unassessable suggested 68 % decrease in STRAE (any grade) but the degree if certainty is unassessable suggested 75 % decrease in STRAE (grade 3-4) but the degree if certainty is unassessable suggested 90 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 79 % decrease in Fatigue TRAE (grade 3-4) but the degree if certainty is unassessable suggested 98 % decrease in Febrile neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 98 % decrease in Leucopenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 100 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Febrile neutropenia AE (grade 3-4) but the degree if certainty is unassessable suggested 98 % decrease in Leucopenia AE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Neutropenia AE (grade 3-4) but the degree if certainty is unassessable	-

non squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) non squamous cell - mNSCLC - L2 non squamous - mNSCLC - L2 - all population

versus docetaxel